Responsibilities of the Joint Research Committee. The JRC shall be responsible for (a) planning and overseeing research under this Agreement, including establishing, reviewing and recommending modifications and updates to the Work Plans; (b) receiving and reviewing relevant data and other information obtained by either Party in connection with the Research Program and monitoring and reporting to the Parties on activities conducted pursuant to the Work Plans; (c) resolving Disputes between the Parties; and (d) such other functions as expressly specified hereunder or as agreed by the Parties.
Responsibilities of the Joint Research Committee. The Joint Research Committee shall be responsible for directing, coordinating and supervising the research and development activities of the Parties during Phase A. In particular, the Joint Research Committee shall
(i) review and endorse the initial Research Plan proposed by the Parties according to Section 2.2;
(ii) review and update the Research Plan on an ongoing basis as set forth in Section 2.2,
(iii) receive regular reports from each Party’s Alliance Manager on, and monitor, the conduct, progress and results of each Party’s activities under the Research Plan,
(iv) agree in advance, review and approve the Shared Costs that the Parties are entitled to incur in Phase A,
(v) resolve any issues referred to it by the Parties in accordance with Section 17.9.
Responsibilities of the Joint Research Committee. The Joint Research Committee shall be responsible for making decisions in relation to the Research Program, including without limitation:
(a) to designate Pre-lead Compounds and Lead Compounds for further research and Preclinical Compounds for selection by the Parties for development and commercialization as provided in Section 2.12; and
(b) to determine the accomplishment of concept validation and other milestone components (including achievement of the First, Second and Third Target Milestones) set forth in the Annual Research Plan. No ICAgen Compound or YAMANOUCHI Compound may be designated by the Joint Research Committee as a Lead Compound after the end of the Research Program or as a Preclinical Compound more than [**] after the end of the Research Program. If an ICAgen Compound or a YAMANOUCHI Compound is designated by the Joint Research Committee as a Preclinical Compound after the end of the Research Program, then the Clinical Compound Selection Period provided in Section 2.12 shall, with respect to such Preclinical Compound, be extended for a period of time (not to exceed [**]) equal in duration to the period of time from the end of the Research Program to such designation by the Joint Research Committee.
Responsibilities of the Joint Research Committee. During the pendency of the Research, the JRC shall be the primary vehicle for interaction between the Parties with respect to the Research. Without limiting the foregoing, the JRC shall be responsible for: (i) reviewing, approving and amending the Research Plan; (ii) recommending whether patents should be filed jointly or independently; (iii) reviewing and approving publications proposed by either Party with respect to results of the Research; (iv) monitoring the progress of Research; (v) reviewing patent filings; and
Responsibilities of the Joint Research Committee. During the pendency of the Research, the JRC shall be the primary vehicle for interaction between the Parties with respect to the Research. Without limiting the foregoing, the JRC shall be responsible for: (i) reviewing, approving and amending the Research Plan; (ii) directing, managing and monitoring the progress of the Research; (iii) identifying to the parties that the criteria for particular changes to the Research Plan arising from changes in the Phase Transitions by RPR have been met; (iv) [*], and (v) reviewing and commenting upon (but not approving) the [*] of the Parties as provided in Article 7. The Research Plan shall contain the specific research objectives to be achieved according to the Phase Transition Criteria document attached hereto as Exhibit A, the specific responsibilities of the Parties, the timeline and budget for the Research, and the total number of FTEs to be devoted by each Party to the Research. Each Party shall disclose to the other proposed agenda items in advance of each meeting of the JRC.
Responsibilities of the Joint Research Committee. The Joint Research Committee shall, among other things, (i) oversee the coordination, implementation and conduct of the Research Project; (ii) review the status and progress of the conduct of the Research Project; (iii) discuss, negotiate and approve the Quarterly Research Project Activities (as defined in Section 4(e) of this Agreement) and Quarterly Research Project Payment (as defined in Section 4(f) of this Agreement) for each Quarterly Research Project Period (as defined in Section 4(g) of this Agreement); (iv) determine if changes or additions are needed to the Research Project or the estimated time frames or estimated budget of the number and cost of the FTEs set forth in the Research Project Estimated Schedule and Budget; (v) approve and implement any changes or additions to the Research Project or the estimated time frames or estimated budget of the number and cost of the FTEs set forth in the Research Project Estimated Schedule and Budget; and (vi) facilitate on-going communications between the Parties.
